Immunoglobulin Replacement Therapy

Introduction to IVIG Therapy

The American Academy of Allergy, Asthma, and Immunology guidelines support immunoglobulin replacement therapy for patients with significant hypogammaglobulinemia (low IgG levels), documented impaired antibody production, and history of recurrent infections 1, 2, 3

Patients with undetectable or severely reduced immunoglobulin isotypes, failure to produce protective antibodies after vaccination, and abnormal B-cell numbers or function are candidates for immunoglobulin replacement therapy, as stated by the American Academy of Allergy, Asthma, and Immunology 2
A history of recurrent or severe bacterial infections, and infections despite appropriate antibiotic therapy, also support the use of immunoglobulin replacement therapy, as recommended by the American Academy of Allergy, Asthma, and Immunology 3
Patients with anatomic risk factors, such as splenectomy, and those with functional antibody deficiency, characterized by laboratory evidence of antibody deficiency and clinical manifestations, are also candidates for immunoglobulin replacement therapy, according to the American Academy of Allergy, Asthma, and Immunology and the American College of Chest Physicians 2, 4

The initiated dose of Octagam 25 grams every 4 weeks is appropriate for initial therapy, with dosing adjustments based on clinical response and trough IgG levels, as recommended by guidelines from reputable sources such as the Centers for Disease Control and Prevention 1
Regular monitoring of trough IgG levels is recommended, and clinical response should be assessed by tracking infection frequency and severity, with the goal of maintaining trough serum IgG concentrations >400-500 mg/dL for patients with hypogammaglobulinemia, according to the American Academy of Allergy, Asthma, and Immunology 1

IVIG is considered the more appropriate first-line therapy for patients with low IgG and impaired vaccine response, rather than antibiotic prophylaxis, which may be considered for some patients with recurrent infections but is not suitable for this specific case, as supported by guidelines from the World Journal of Emergency Surgery and the Infectious Diseases Society of America 5
Failed vaccination response, indicated by the inability to mount protective antibody responses to pneumococcal vaccination despite repeated attempts, also supports the use of immunoglobulin replacement therapy, as stated by the American Academy of Allergy, Asthma, and Immunology 3